NeuroMetrix, Inc. (NURO) |
4.58 0.22 (5.05%) 05-01 16:00 |
Open: | 4.36 |
High: | 4.69 |
Low: | 4.3304 |
Volume: | 35,587 |
Market Cap: | 9(M) |
PE Ratio: | -1.16 |
Exchange: | NASDAQ Capital Market |
Industry: | Medical - Devices |
Sector: | Healthcare |
Technical analysis | ||||
![]() |
||||
sell | buy |
Resistance 2: | 5.48 |
Resistance 1: | 4.69 |
Pivot price: | 4.46 |
Support 1: | 4.42 |
Support 2: | 4.26 |
52w High: | 4.73 |
52w Low: | 2.66 |
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
EPS | -3.960 |
Book Value | 6.980 |
PEG Ratio | 0.00 |
Gross Profit | 0.830 |
Profit Margin (%) | -257.39 |
Operating Margin (%) | -335.84 |
Return on Assets (ttm) | -27.9 |
Return on Equity (ttm) | -45.4 |
Fri, 02 May 2025
electroCore's $4.49/Share NeuroMetrix Buyout Expands Chronic Pain Treatment Portfolio - Stock Titan
Fri, 02 May 2025
NeuroMetrix finalizes acquisition by electroCore - Investing.com
Fri, 02 May 2025
electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies - GlobeNewswire
Mon, 06 Jan 2025
NEUROMETRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NeuroMetrix, Inc. - NURO | FinancialContent - FinancialContent
Mon, 06 Jan 2025
Here’s Why NeuroMetrix, Inc. (NASDAQ:NURO) Is Among the Best Diabetes Stocks to Buy Under $10 - Yahoo Finance
Tue, 17 Dec 2024
electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness - GlobeNewswire
![]() StockChart iOS |
![]() StoxlineLite iOS |
![]() StoxlineLite iOS |
![]() OptionCalc iOS |
![]() StockChart Android |
![]() StoxlineLite Android |
![]() StoxlinePro Android |
![]() OptionCalc Android |